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Abstract
Peripheral biomarkers of Alzheimer’s disease (AD) reflecting early neuropathological change are critical to the development
of treatments for this condition. The most widely used indicator of AD pathology in life at present is neuroimaging evidence
of brain atrophy. We therefore performed a proteomic analysis of plasma to derive biomarkers associated with brain
atrophy in AD. Using gel based proteomics we previously identified seven plasma proteins that were significantly associated
with hippocampal volume in a combined cohort of subjects with AD (N=27) and MCI (N=17). In the current report, we
validated this finding in a large independent cohort of AD (N=79), MCI (N=88) and control (N=95) subjects using
alternative complementary methods—quantitative immunoassays for protein concentrations and estimation of pathology
by whole brain volume. We confirmed that plasma concentrations of five proteins, together with age and sex, explained
more than 35% of variance in whole brain volume in AD patients. These proteins are complement components C3 and C3a,
complement factor-I, c-fibrinogen and alpha-1-microglobulin. Our findings suggest that these plasma proteins are strong
predictors of in vivo AD pathology. Moreover, these proteins are involved in complement activation and coagulation,
providing further evidence for an intrinsic role of these pathways in AD pathogenesis.
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Introduction
There is an urgent need for biomarkers of Alzheimer’s disease
(AD); especially to detect the early stages of disease. Such
biomarkers have considerable potential in both clinical practice
and research where they may accelerate the development of novel
disease-modifying treatments [1]. In both the United States and
Europe public/private consortia are conducting trials to discover
such biomarkers [2,3]. Strategies for biomarker discovery in AD
are well advanced using neuroimaging and assays of candidate
proteins in cerebrospinal fluid (CSF). However these methods may
not be widely available for use in large, community based,
multicentre studies or in the routine clinical care of large numbers
of frail elderly people.
Approaches to biomarker discovery in AD have traditionally
focused on demonstrating the power of candidate biomarkers to
discriminate between cases and controls and have therefore relied
upon standard sensitivity and specificity measures to evaluate the
clinical utility of such biomarkers. We have previously used this
strategy in a large proteomic analysis of plasma to derive a panel of
proteins differentiating AD from age-matched healthy control
subjects [4]. Employing two dimensional gel electrophoresis
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spectrometry (LC/MS/MS), we identified 15 plasma proteins
whose concentrations were significantly different in AD compared
to control subjects. Using semi-quantitative Western blotting, we
subsequently validated two proteins; complement factor-H (CFH)
and alpha2-macroglobulin (A2M) as AD-specific plasma biomark-
ers.
Although the above standard approach relying upon the binary
distinction of differentiating disease from control may be useful, it
may not be suitable for the identification of biomarkers accurately
reflecting or measuring in vivo disease pathology in subjects with
early or established AD. This attribute is in turn a key criterion for
an AD biomarker [5] and one that might be especially useful in the
setting of clinical trials for the enrichment of patient populations
with varying severities of disease pathology. Case versus control
approaches to biomarker discovery in AD also ignore the
considerable overlap of pathologies such as those underlying
vascular injury which are commonly observed in post mortem
studies of AD patients [6]. An alternative approach is to therefore
seek novel markers based primarily on their association with
established metrics of disease pathology. We have successfully used
this approach recently to identify plasma clusterin concentration as
a marker of pathology in AD [7]. In the current study, we report
the validation of a panel of plasma proteins associated with brain
atrophy in AD.
Methods
Subjects and samples
We recruited 262 subjects (AD, N=79); MCI, N=88; and
control N=95) as part of AddNeuroMed, a multi-centre
European study for the identification of AD biomarkers.
Assessment, imaging and diagnostic procedures have been
previously reported [8] [2].
Ethics committee approval
This study was approved by the South London and Maudsley
NHS Foundation Trust ethics committee. Ethics committee
approval was also obtained at each of the participating centres
in accordance with the Alzheimer’s Association’s published
recommendations [9].
MRI Data Acquisition
The primary outcome measure for validation was whole brain
volume; chosen as an in vivo measure of pathology [10,11]. Whole-
brain sagittal three-dimensional MP-RAGE images (TR=8.6,
TE=3.8, 2566192 acquisition matrix, 18061.2 mm slices) were
obtained from all subjects on a 1.5T MR system at each of the 6
participating centres. Whole brain volumes, consisting of grey and
white matter with CSF excluded and normalised to intracranial
volume, were determined using an artificial neural network
classifier [12]. Quality control of the MR systems was performed
using the ADNI test object [13] and comparability between
centres assured by repeat scanning of two volunteers on each
system (whole brain volume coefficient of variation=1.7%).
Selection of candidate biomarkers associated with brain
atrophy
The selection of candidate plasma proteins for quantitative
immunoassays in this report was based upon an earlier discovery-
phase study in a separate cohort of AD (N=27) and MCI (N=17)
subjects that identified the concentrations of seven plasma proteins
as being significantly associated with hippocampal volume. These
seven proteins were complement C3, c-fibrinogen (Fibrinogen
gamma chain), serum albumin, complement factor-I (CFI),
clusterin, a1-microglobulin, and serum amyloid-P (SAP). The
detailed description of these discovery-phase 2DGE and LC/MS/
MS experiments has been previously reported [7]. Briefly, the
discovery-phase studies used optical densities of silver-stained
protein spots in 2DGE gels and examined their association with
hippocampal volumes estimated by manual tracing. Of these seven
proteins, we recently validated plasma clusterin concentration as a
candidate AD biomarker by reporting its association with disease
severity, pathology and progression [7]. In the present report, our
main aim was to examine the association with AD pathology of all
the other plasma proteins (except clusterin and albumin) identified
in our previous discovery-phase study. We therefore selected
complement C3 and its cleavage product C3a, c-fibrinogen,
complement factor-I (CFI), a1-microglobulin, and serum amyloid-
P (SAP) for validation in the current report using alternative
methods in a large independent cohort of AD (N=79), MCI
(N=88) and control (N=95) subjects. We employed quantitative
immunoassays to measure protein concentrations and automated
estimates of whole brain volume using MRI images for
measurement of brain atrophy.
Immunoassays
We used ELISA-based immunoassays where available (C3,
C3a, and a-1-microglobulin) and semi-quantitative Western
blotting in the remainder (CFI, SAP, c-fibrinogen) (table S1 and
table S2). All samples were run in quadruplicate except a-1-
microglobulin which was run in duplicate. For Western blots, a
reference plasma sample (consisting of at least 15 combined
plasma samples from individuals collected in different centres) was
run in duplicate on every gel and signals for CFI, SAP and c-
fibrinogen were normalised to the mean value of this sample.
Statistics
Inter-group differences in age, sex and education were tested by
univariate general linear models. Differences in neuroimaging
measures, MMSE and plasma concentrations of candidate
biomarkers were tested by univariate general linear models after
covarying for age. In order to account for the effects of age and
sex, we first included these two variables alone as predictors of
variance in whole brain volume in each of the AD, MCI and
control groups using partial least squares (PLS) regression.
Subsequently, the plasma protein concentrations of the candidate
biomarkers were scaled to unit variance and together with age and
sex, were entered into PLS regression analyses to derive models
predictive of whole brain volume in each group (unit variance
scaling gives both high and low variance variables equal
importance in the model). In exploratory analyses, education
was included as a covariate in all the PLS regression models. As it
was found not to contribute to variance in whole brain volume, it
was excluded from the final optimal PLS model.
The predictive ability of the PLS model was assessed using a
seven-fold cross validation procedure and summarised as the root
mean square error of prediction (RMSEP):
RMSEP~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X n
i~1
^ y yi{yi ðÞ
2
n
v u u u t
where y ˆi-yi represents the residuals between predicted and actual
values of whole brain volume. The RMSEP is analagous to a
standard deviation of the differences between predicted and actual
values of whole brain volume.
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We have previously reported the gel-based proteomics discovery
of candidate plasma proteins associated with hippocampal atrophy
in AD [7]. Having previously identified a set of proteins associated
with hippocampal volume in disease state, we set out, in the
current study, to validate these findings using alternative methods
in a larger, independent cohort of subjects. We established, a priori,
outcome criteria for validation; the primary outcome being
association with whole brain volume, chosen both as an excellent
discriminator of disease state [10,11] and a measure of atrophy
readily suitable for analysis of MRI data obtained from a multi-
centre study with fewer problems of rater-variability than manual
estimates of hippocampal volume. Secondary outcomes were
differences in concentrations of markers between diagnostic groups
and/or correlation with clinical measures of disease severity
(MMSE for cognition and Clinical Dementia Rating for global
severity).
Subject characteristics
Patients with AD (N=79; 75.666.0 years) were slightly older
than both MCI (N=88; 74.667.0 years; non-significant) and
control subjects (N=95; 73.166.7 years; p=0.005; LSD post-hoc
test). There were no significant differences in gender between the
groups. Whole brain volume was significantly decreased in the AD
group compared to both control (p,0.001) and MCI (p,0.001)
subjects (table 1). Table 2 shows the mean plasma concentrations
of the assayed proteins with the corresponding standard errors.
Partial least squares regression of whole brain volume
against predictor variables
In initial exploratory analyses, we first examined unadjusted
univariate associations between concentrations of the six plasma
proteins and whole brain volume in the AD group (table 3). Age
and sex together accounted for 19.7% of variance in whole brain
volume in the AD group. Single component PLS models were then
fitted to whole brain volume wherein the predictor variables
included age, sex, concentrations of the six plasma proteins and
the ratio of complement C3:C3a. The latter measure was included
as a predictor variable as it is an accepted marker of complement
activation [14]. The model explaining the greatest variance in
whole brain volume was in the AD group, where a single-
component PLS model explained 37.7% of the variance (R2Y) in
brain volume (Q2 provides an estimate of how well the model
predicts the Y data and R2X denotes variance explained in the
predictor variables) (table 2). A further refinement of this model
was achieved by eliminating those predictor variables contributing
the least to explaining variance in whole brain volume. Inspection
of the variable influence on projection (VIP) plot showed that the
ratio of C3:C3a and SAP concentration contributed least to
explaining variance in whole brain volume in AD and these
Table 1. Sample characteristics of AD, MCI and control participants in this study.
AD (n=79) MCI (n=88) Control (n=95)
Sex (M/F) 28/51 42/46 43/52
Age (years) 76.0 (6.0)* 74.6 (5.9) 73.1 (7.0)
Education (years) 7.9 (4.0)
{ 9.2 (4.3)
{{ 10.8 (4.8)
Disease duration (years) 3.9 (2.4)
MMSE 20.9 (4.6)
1 27.3 (1.6)
11 29 (1.2)
Whole brain volume normalised to total ICV. 0.82 (0.03)
","" 0.85 (0.03) 0.86 (0.030)
Values are expressed as mean 6 (SD).
*Differs from control; p=0.007.
1Differs from control; p,0.001.
11Differs from control; p,0.001.
"differs from control; p,0.001.
""differs from MCI; p,0.001.
{Differs from control; p,0.001.
{{Differs from control; p,0.02.
doi:10.1371/journal.pone.0028527.t001
Table 2. Plasma concentrations of assayed candidate
biomarkers with their corresponding standard errors.
AD MCI Control
C3 (mg/ml) 1588.0 (170.7) 1282.1 (110.5) 1167.1 (65.2)
C3a (ng/ml) 2653.3 (134.5) 2629.9 (136.2) 3064.0 (118.4)
A1M (mg/l) 16.7 (0.94) 17.27 (0.93) 15.58 (1.0)
CFI* 0.86 (0.01) 0.86 (0.01) 0.88 (0.01)
Gamma-fibrinogen* 0.92 (0.01) 0.96 (0.01) 0.94 (0.01)
SAP* 1.12 (0.05) 1.1 (0.04) 1.12 (0.05)
CFI, Gamma fibrinogen and SAP were assayed by Western blotting and their
concentrations are in arbitrary units of optical density*.
doi:10.1371/journal.pone.0028527.t002
Table 3. Univariate associations between plasma
concentrations of assayed candidate biomarkers and whole
brain volume in AD; R=Pearson correlation coefficient; p=2-
tailed statistical significance.
Plasma protein R/p
C3 0.31/0.006
C3a 0.27/0.02
A1M 20.23/0.04
CFI 0.24/0.04
Gamma-fibrinogen 0.24/0.03
SAP 0.05/0.65
doi:10.1371/journal.pone.0028527.t003
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led to deriving a final optimal single-component PLS model with
age, sex, complement C3, C3a, c-fibrinogen, a-1-microglobulin
and CFI that could together explain 38.2% of variance in whole
brain volume in subjects with AD (table 4).
Cross validation of PLS model of plasma proteins
predicting brain volume
The final PLS model for whole brain volume in AD consisting
of age, sex, C3a, C3, c-fibrinogen, a-1-microglobulin and CFI
gave a low RMSEP value of 0.027 indicating good predictive
power (figure 1B).
Internal validation of the PLS model for whole brain
volume in AD
Further ‘internal’ model validation was effected by randomising
the positions of the Y data in relation to their corresponding rows
in the X matrix (typically 100 separate row permutations were
performed) and observing the effect of this randomisation on the
R2Y and Q2 values. Randomisation of the Y data considerably
reduced R2Y and Q2 (figure 1C) in comparison to the original
model, thereby indicating its validity. Furthermore, the results of
this response permutation testing suggest that the likelihood of
deriving a model with comparable predictive ability purely by
chance was less than 1%, further indicating the robustness of the
PLS model for whole brain volume in AD.
Clinical correlations with plasma biomarkers
We also examined the plasma concentrations of these proteins
in relation to diagnosis and clinical measures of severity as
secondary outcomes. Plasma C3 was significantly elevated in AD
(p=0.03) patients relative to controls. We also observed a trend for
association between plasma C3 concentration and MMSE score in
the combined group of AD and MCI subjects (r=20.14,
p=0.07). Plasma c-fibrinogen was significantly increased in
MCI subjects versus AD (p=0.03).
Discussion
We have adopted a novel approach to the discovery of
biologically relevant plasma biomarkers in early AD. Our aim
was to identify peripheral markers of AD by their association with
established neuroimaging measures of pathology and then to
validate these by alternative quantitative methods in a large and
independent test population.
Multiple lines of evidence suggest that peripheral fluids such as
plasma may be a rich source of biomarkers in AD. Such markers
might reflect a systemic metabolic signature of AD or be a change
in plasma secondary to a disease-specific process in the brain [15].
We have previously used a proteomic approach to identify plasma
proteins differentially expressed in established AD [4]. Others
have used arrays of candidate proteins, finding remarkably high
sensitivity and specificity for diagnosis of established AD versus
controls [16]. Both candidate and ‘data-driven’ approaches
(proteomics, transcriptomics etc) tend to use disease status, either
case versus control or control/MCI progression to case, as the
primary outcome variable in discovery studies. Where the
discovery paradigm uses large scale or array-based technologies,
this can result in the identification of potential biomarkers with no
known, or at best, uncertain, involvement in disease. Furthermore
this binary distinction (disease/no disease) may result in the
discovery of biomarkers that show excellent diagnostic or
predictive characteristics but lack sensitivity in relation to disease
progression or severity. To avoid these problems, we sought to
discover, using proteomics, biomarkers where the primary
outcomes were associations with well-established neuroimaging
measures of disease pathology.
In the discovery-phase proteomics study which led us to the
candidate plasma proteins of interest in the current report, we used
hippocampal atrophy as a measure of disease pathology [7]. For
validation of candidate markers in the present study, we chose an
alternative measure of brain atrophy to overcome some of the
limitations of manual hippocampal volumetry. The chief advan-
tage of whole brain over manual estimates of hippocampal volume
Figure 1. Plasma proteins associated with whole brain volume in Alzheimer’s disease. A. Variable influence on projection (VIP) plot
summarising the overall contribution of each predictor variable to the PLS model for brain volume in AD, summed over all components and weighted
according to the Y variation accounted for by each component. Black bars represent variables contributing the least (SAP and C3:C3a) to variance in
the brain volume and therefore eliminated in the final PLS model. B. The result of a seven-round cross validation exercise in which every point
represents test data not used in the model-building. Plots of observed versus predicted values of normalised whole brain volume (WBV) in AD
patients using a single-component PLS model constituted by age, sex, C3a, C3, c-fibrinogen, a-1-microglobulin and CFI (regression line is represented
by the equation: observed value=[1.0060.1266predicted value]+0.000460.102; root mean square error of predictions=0.027). C. Internal validation
of the final PLS model predicting whole brain volume in AD demonstrating clear decreases in model performance as the whole brain volume data are
permuted relative to the predictor variables. R2Y (black triangles) describes how well the derived model fits the data and is the proportion of the sum
of squares explained by the model. Q2 (red squares) describes the predictive ability of the derived model and is the cross validated R2Y. The pair of R2
and Q2 values at the extreme right represent the optimal PLS model constituted by age, sex, C3a, C3, c-fibrinogen, a-1-microglobulin and CFI. The
cluster of R2 and Q2 values at the left represent the PLS models derived by permutating the whole brain volume data relative to the predictor
variables and show a clear decline in performance.
doi:10.1371/journal.pone.0028527.g001
Table 4. Summary of the partial least squares (PLS) models fitted to whole brain volume in AD; R2X-variance explained in the
predictor variables; R2Y-variance explained in the response variable i.e. whole brain volume; Q2-goodness of prediction of the PLS
model.
Number of components Predictor variables R2X R2Y Q2
1 Age, Sex 0.53 0.197 0.187
1 Age, Sex, C3, C3a, C3:C3a, CFI, SAP, c-fibrinogen, a1-microglobulin 0.186 0.377 0.295
1* Age, Sex, C3, C3a, CFI, c-fibrinogen, a1-microglobulin 0.277 0.382 0.311
*Denotes final optimal PLS model, after eliminating those variables contributing the least to explaining variance in whole brain volume.
doi:10.1371/journal.pone.0028527.t004
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subject to inter-rater variability and is therefore readily utilisable in
large multi-centre studies such as ours.
Moreover, like hippocampal atrophy, whole brain atrophy is
also an early event in the disease, an excellent discriminator of
disease state and correlates closely with longitudinal measures of
atrophy [10,11,17]. Automated cross-sectional measurements of
normalised whole brain volume have also been compared with
longitudinal measures of rates of whole brain atrophy [11]. These
studies have reported that the cross-sectional measurement of
whole brain volume is nearly as powerful a discriminant between
AD patients and controls as longitudinal observations on rates of
whole brain atrophy. Equally importantly, there is a highly
significant correlation between cross-sectional and longitudinal
measures of whole brain atrophy in AD. The latter has also been
used as a neuroimaging biomarker in a clinical trial of AD [18].
Cross-sectional measurement of whole brain volume was recently
shown to differentiate between MCI subjects progressing to AD
and those that remained stable [10]. In subjects with MCI and
established AD, there was also a highly significant association
between baseline whole brain volume and CSF Ab1–42, levels,
further suggesting that this neuroimaging measure reflects an
integral feature of AD neuropathology [19].
Our previous discovery-phase study demonstrated that seven
plasma proteins were significantly associated with hippocampal
volume in a combined cohort of AD and MCI subjects [7]. In the
current report, we confirmed a significant association between
these plasma proteins and whole brain volume in AD. Five
proteins from the original panel of candidate biomarkers explained
18% of variance in brain volume in the AD group. Together with
age and sex, these proteins could explain more than 35% of
variance in brain volume in AD patients. Further cross validation
and response permutation testing confirmed a robust predictive
power of this PLS model for whole brain volume in AD.
Our results demonstrate that we have identified a panel of
plasma proteins that are predictors of current disease severity as
measured by well-established neuroimaging markers of pathology.
Moreover, their association with core neuropathological features
of AD suggests that these proteins are not merely non-specific
markers of disability in the elderly, but biologically relevant
proteins accurately reflecting disease pathology.
Most of the plasma proteins associated with neuroimaging
measures of disease pathology in this study are components or
regulators of the complement system and coagulation pathway.
Multiple lines of evidence support a role for the complement
system in the pathogenesis of AD [20,21] and recent proteomic
studies have implicated complement proteins in the CSF,
including C3a both as biomarkers of established AD [22] as well
as predictors of conversion to AD in MCI subjects [23].
Fibrinogen is yet another candidate biomarker common to
findings in the current report and a recent proteomic analysis in
CSF that identified biomarkers discriminating AD from control
samples [24]. It must be noted that very few studies have directly
addressed the associations between peripheral concentrations of
complement modulating proteins and their levels in the central
nervous system. This is an important consideration in the
interpretation of blood biomarker studies and their relevance to
brain pathology in AD. We have recently attempted to address this
question and reported that the plasma concentration of clusterin, a
known complement modulator is significantly associated with its
expression in brain regions vulnerable to AD pathology [25]. A
significant association between c-fibrinogen and brain volume
observed in the current report is also interesting in the light of data
demonstrating an increased risk of dementia in subjects with
elevated plasma levels of fibrinogen [26].
Our present study suggesting that complement regulators and
complement-related proteins are candidate biomarkers of AD also
extends findings from our previous proteomic analysis of plasma
implicating complement factor-H (CFH) as an AD-specific plasma
biomarker [4,27].
A limitation of the present study that must be acknowledged is
its cross-sectional design. Therefore, while our results strongly
suggest that we have identified a panel of biomarkers that reflect
current disease status by their association with in vivo disease
pathology, we have not yet extended these findings to examine the
utility of these proteins in measuring disease progression.
However, our findings merit independent confirmation by other
groups and if replicated, are likely to be rapidly extended to
longitudinal studies that examine their utility as markers of disease
progression or treatment response in clinical trials. It must also be
noted that the use of MRI-derived brain volume estimates in this
and the majority of other AD biomarker studies may ignore the
significant contribution of ischemic microvasular pathology to AD
pathogenesis. This issue merits consideration in the interpretation
of these studies, especially because of the paucity of reliable
imaging biomarkers of microvascular brain injury [28].
In summary, we combined a proteomic and neuroimaging
approach to the discovery of biologically relevant biomarkers in
AD. Variation in just five plasma proteins, together with age and
sex accounts for more than a third of the variance in brain volume
suggesting that these proteins are likely to be strong predictors of
pathology in vivo. We therefore suggest that plasma markers have
the potential for future use in large scale community based settings
– either in clinical practice or research. Furthermore, these
findings add weight to the growing evidence implicating the
complement and coagulation pathways in AD pathogenesis.
Supporting Information
Table S1 Details of reagents used in Western Blot
assays.
(DOC)
Table S2 Details of reagents used in ELISA assays.
(DOC)
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